US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bayer A.G.

15.66

-0.0100-0.06%

Post-market: 15.660.00000.00%16:00 EST

Volume:544.42K

Turnover:8.52M

Market Cap:61.54B

PE:-37.45

High:15.72

Open:15.63

Low:15.60

Close:15.67

52wk High:15.98

52wk Low:7.65

Shares:3.93B

Float Shares:3.93B

Volume Ratio:0.34

T/O Rate:0.01%

Dividend:0.03

Dividend Rate:0.20%

EPS(TTM):-0.4181

EPS(LYR):-0.6723

ROE:-4.56%

ROA:4.34%

PB:1.91

PE(LYR):-23.29

Loading ...

Overview Company News Filings

Bayer New Stroke Drug Can Withstand Competition

New Type of Blood Thinner Approved to Prevent Repeat Strokes

Bayer Has Path Toward Better Cash Generation

Bayer Investors Await Roundup Settlement

Bayer Guidance Raise Reflects Quarterly Earnings Beat

Bayer Says China Approved Asundexian, First Factor XIa Inhibitor Approved Worldwide

Benzinga Earnings

Bayer Shares Jump After Pharma Recovery Prompts Outlook Raise

Bayer Results to be Well-Received

Bayer Q3 Adj. EPS $0.09 Misses $0.13 Estimate, Sales $11.570B Miss $11.700B Estimate

Benzinga Earnings

Bayer Trial Win Matters More than it Seems

Bayer Takes Another Step Toward Litigation Containment

Bayer Wins First U.S. Trial over Roundup Since Supreme Court Ruling

Bayer’s Vericiguat Heart Failure Study in India: What the Real‑World Data Could Mean for BAYRY

Bayer Gets China Approval for Stroke-Prevention Drug in Global First for New Class

Bayer Expands Real-World Kidney Data For Finerenone, Eyeing Long-Term Upside For BAYRY

Bayer Advances Nurandociguat Tablet Study, Signaling Steady Progress in CKD Pipeline

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Bayer to invest $2.2B in new manufacturing site in New Albany, Ohio

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

Bayer announces FDA accepts Lynkuet sNDA for Priority Review

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/BAYRY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":15.66,"timestamp":1794603600000,"preClose":15.67,"halted":0,"volume":544421,"hourTrading":{"tag":"盘后","latestPrice":15.66,"preClose":15.66,"latestTime":"16:00 EST","volume":1298,"amount":20315.940000000002,"timestamp":1794603640964,"change":0,"changeRate":0,"amplitude":0.000639},"delay":15,"changeRate":-0.000638162093171652,"floatShares":3929259738,"shares":3929696328,"eps":-0.41815,"marketStatus":"Closed","change":-0.01,"latestTime":"11-13 16:00:40 EST Delay","open":15.63,"high":15.715,"low":15.6,"amount":8523143.572799996,"amplitude":0.007339,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.41815,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":5,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":15.67,"volumeRatio":0.34397},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"4.34%","roe":"-4.56%","lyrEps":-0.672343,"volumeRatio":0.34397,"shares":3929696328,"dividePrice":0.031526,"high":15.715,"amplitude":0.007339,"preClose":15.67,"low":15.6,"week52Low":7.65,"pbRate":"1.91","psRate":"1.22","week52High":15.98,"institutionHeld":0.0017,"latestPrice":15.66,"eps":-0.41815,"divideRate":0.002013,"volume":544421,"delay":15,"ttmEps":-0.41815,"open":15.63,"prevYearClose":10.82,"prevWeekClose":15.33,"prevMonthClose":13.99,"prevQuarterClose":13.5,"fiveDayClose":15.33,"twentyDayClose":12.47,"sixtyDayClose":14.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"","actualEps":null},{"date":"2026-04-28","symbol":"BAYRY","amount":0.031526,"announcedDate":"2026-04-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-28","defaultRemindTime":1777383000000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-11","payableDate":"2026-04-28","currency":"USD","dateTimestamp":1777348800000,"payDate":"2026-05-11"},{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"},{"executeDate":"2023-05-02","recordDate":"2023-05-03","paymentDate":"2023-05-15","value":0.6318,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1783918800000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2682983315","title":"Bayer New Stroke Drug Can Withstand Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=2682983315","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682983315?lang=en_us&edition=fundamental","pubTime":"2026-11-10 22:05","pubTimestamp":1794319500,"startTime":"0","endTime":"0","summary":"1405 GMT - Bayer's new stroke drug looks well positioned to withstand competition, according to analysts at Bank of America. The drug asundexian is likely to benefit from good adoption and could generate annual sales of 3 billion euros at its peak, the bank estimates. Rivals Bristol Myers Squibb and Johnson & Johnson are working together on a competitor medicine candidate, milvexian. Upcoming data on milvexian could prompt Bank of America to revise its asundexian estimate, but most scenarios it is contemplating would result in upgrades. Even if milvexian ends up working in secondary stroke prevention and stroke prevention in atrial fibrillation, consensus estimates for asundexian peak sales of 2 billion euros would face limited risk, the analysts say. Bayer shares rise 0.2%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","LU1670710588.SGD","IE0002141913.USD","LU0306806265.USD","LU0321505868.SGD","LU1670711123.USD","BK4581","LU1261432733.SGD","BK4588","LU0985481810.HKD","LU0432979614.USD","LU2360032135.SGD","LU0237698245.USD","LU0267386448.USD","BK4532","LU1868836914.USD","LU0289739699.SGD","LU1868837136.USD","LU1983299246.USD","LU0225284248.USD","BAYRY","LU1718418525.SGD","LU1670710661.SGD","IE00BJJMRZ35.SGD","LU2125154935.USD","LU1236620750.USD","LU1032466523.USD","LU2596442595.SGD","LU1571399168.USD","LU0882574055.USD","LU1323610961.USD","LU1074936037.SGD","LU1093756168.USD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU2242652126.USD","LU1670711040.USD","LU2125154778.USD","IE00B2B36J28.USD","LU2133065610.SGD","BK4585","FTXH","IE00BSNM7G36.USD","IHE","LU1868837300.USD","BK4534","IE00BFXG1179.USD","LU1585245621.USD","BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682733778","title":"New Type of Blood Thinner Approved to Prevent Repeat Strokes","url":"https://stock-news.laohu8.com/highlight/detail?id=2682733778","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682733778?lang=en_us&edition=fundamental","pubTime":"2026-11-10 06:50","pubTimestamp":1794264600,"startTime":"0","endTime":"0","summary":"A new type of blood thinner approved on Monday is the first shown in testing to prevent repeat strokes without significantly increasing a person's bleeding risk.Most patients who survive a clot-relate","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680058436","title":"Bayer Has Path Toward Better Cash Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2680058436","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680058436?lang=en_us&edition=fundamental","pubTime":"2026-11-04 19:42","pubTimestamp":1793792520,"startTime":"0","endTime":"0","summary":"1142 GMT - Bayer's legal battles have hit the company's cash flows in recent years, but the group has a path to better cash generation ahead that could aid its debt-reduction efforts, analysts at Bank of America say in a research note. With litigation mostly resolved, the cash-flow outlook for the German group and the growth prospects for its pharmaceutical business could draw investors' attention, the analysts say. Bayer's guidance for 2027 will be a key focus, they add. Bank of America sees potential for Bayer to generate between 3 billion and 5 billion euros in free cash flow over the medium term. Shares rise 2.9%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VFH","LU0648001328.SGD","IE00BLSP4239.USD","LU0203347892.USD","FNCL","LU1280957306.USD","LU2596442595.SGD","LU0306807586.USD","BK4553","BK4207","LU2129689431.USD","LU0203345920.USD","IYG","LU0211331839.USD","LU0310800965.SGD","IE00BFXG1179.USD","LU0170899867.USD","LU0971096721.USD","LU1804176565.USD","UYG","BK4588","LU0098860793.USD","BAC","LU0106831901.USD","LU1894683264.USD","LU1880398471.USD","IE00B19Z3581.USD","XLF","IE00BLSP4452.SGD","LU0130102774.USD","IYF","BK4559","LU0320765489.SGD","LU0321505439.SGD","LU1035773651.USD","LU1201861249.SGD","KBWB","IE00B1BXHZ80.USD","LU1074936037.SGD","TFNS","LU0052756011.USD","LU1668664300.SGD","LU0256863902.USD","LU0314106906.USD","FTXO","LU1506573853.SGD","BK4504","BAYRY","BK4585","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680034764","title":"Bayer Investors Await Roundup Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2680034764","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680034764?lang=en_us&edition=fundamental","pubTime":"2026-11-04 18:30","pubTimestamp":1793788200,"startTime":"0","endTime":"0","summary":"1030 GMT - Bayer reported strong results for the third quarter, but investors' main focal point remains the proposed settlement for litigation over its Roundup weedkiller, UBS says in a note. Executives at the German agricultural and pharmaceutical group said during an earnings call Tuesday that a decision on the settlement's approval is expected before Christmas. The number of plaintiffs who opted out of the settlement is subject to change, since some revoked their initial requests after recent rulings in favor of the company, the analysts say. Beyond the settlement, investors also await the launch of the stroke-prevention drug asundexian in the U.S. and data from rival product milvexian, the analysts add. UBS lifts its target price on Bayer stocks to 66 euros from 62 euros. Shares rise 2.8% to 53.28 euros.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","ISBC","BK4007","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680722109","title":"Bayer Guidance Raise Reflects Quarterly Earnings Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2680722109","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680722109?lang=en_us&edition=fundamental","pubTime":"2026-11-03 22:07","pubTimestamp":1793714820,"startTime":"0","endTime":"0","summary":"1407 GMT - Bayer raised its full-year guidance, but the increase seems to reflect the margin by which its third-quarter earnings beat expectations, analysts at Jefferies write in a note to clients. A strong performance in the German company's pharmaceutical division drove group-level adjusted Ebitda to exceed consensus estimates by 14%, or 200 million euros, the analysts say. This could be the result of one-off items, as the group's quarterly core EPS missed expectations, they add. Since Bayer raised its full-year adjusted Ebitda guidance by 200 million euros, it seems like it only took the size of its third-quarter beat forward into the full year, according to Jefferies. Shares rise 6.6%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680440137","title":"Bayer Says China Approved Asundexian, First Factor XIa Inhibitor Approved Worldwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2680440137","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680440137?lang=en_us&edition=fundamental","pubTime":"2026-11-03 18:33","pubTimestamp":1793702033,"startTime":"0","endTime":"0","summary":"Bayer Says China Approved Asundexian, First Factor XIa Inhibitor Approved Worldwide","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/BAYRY","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680274610","title":"Bayer Shares Jump After Pharma Recovery Prompts Outlook Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2680274610","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680274610?lang=en_us&edition=fundamental","pubTime":"2026-11-03 17:06","pubTimestamp":1793696760,"startTime":"0","endTime":"0","summary":"Bayer shares rose after the German group raised its full-year earnings guidance, citing a recovery in its pharmaceutical business that allowed it to mitigate market pressures at its agricultural and c","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680480127","title":"Bayer Results to be Well-Received","url":"https://stock-news.laohu8.com/highlight/detail?id=2680480127","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680480127?lang=en_us&edition=fundamental","pubTime":"2026-11-03 16:03","pubTimestamp":1793692980,"startTime":"0","endTime":"0","summary":"0803 GMT - Bayer shares are likely to react positively to the German agricultural and pharmaceutical group's third-quarter results, analysts at J.P. Morgan say in a research note. The company lifted its underlying Ebitda guidance due to a better-than-expected performance in its pharma division, and its new outlook points to upgrades to consensus expectations, the analysts say. Moreover, both sales and underlying Ebitda for the third quarter exceeded consensus expectations. \"Overall, we expect the results to be well received given the pharma-driven Ebitda beat and guidance raise, and expect the shares to outperform today by 2-3%,\" they add.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680071761","title":"Bayer Q3 Adj. EPS $0.09 Misses $0.13 Estimate, Sales $11.570B Miss $11.700B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2680071761","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680071761?lang=en_us&edition=fundamental","pubTime":"2026-11-03 15:05","pubTimestamp":1793689541,"startTime":"0","endTime":"0","summary":"Bayer (OTC:BAYRY) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.13 by 30.77 percent. This is a 35.71 percent decrease over earnings of $0.14 per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62806460/bayer-q3-adj-eps-0-09-misses-0-13-estimate-sales-11-570b-miss-11-700b-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679120219","title":"Bayer Trial Win Matters More than it Seems","url":"https://stock-news.laohu8.com/highlight/detail?id=2679120219","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679120219?lang=en_us&edition=fundamental","pubTime":"2026-10-30 20:07","pubTimestamp":1793362020,"startTime":"0","endTime":"0","summary":"1207 GMT - Bayer's win in a Missouri trial over the company's Roundup weedkiller is more meaningful than it might seem, given that it represents the first courtroom test of plaintiffs' alternative routes after a June ruling from the U.S. Supreme Court, analysts at Jefferies write in a note to clients. \"While one verdict should not be over-extrapolated, we think it provides a positive first datapoint on plaintiffs' remaining litigation routes,\" the analysts say. The Supreme Court ruling pre-empted failure-to-warn claims, historically a key argument in Roundup litigation, they add. In the latest trial, the jury sided with Bayer's Monsanto on design defect, fraud and negligence claims and rejected them unanimously after a deliberation of just two hours, Jefferies says. Shares rise 3.6%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679129489","title":"Bayer Takes Another Step Toward Litigation Containment","url":"https://stock-news.laohu8.com/highlight/detail?id=2679129489","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679129489?lang=en_us&edition=fundamental","pubTime":"2026-10-30 17:58","pubTimestamp":1793354280,"startTime":"0","endTime":"0","summary":"0957 GMT - Bayer took another step toward containing litigation risks with a favorable court ruling in Missouri in a case over its Roundup weedkiller, J.P. Morgan analysts say in a note. With failure-to-warn claims no longer available due to a U.S. Supreme Court ruling earlier this year, a Missouri Circuit Court jury sided with the company on the design defect, fraud, and negligence claims that each of the three plaintiffs pursued, the analysts say. \"We see this as another positive step to the overall containment of the glyphosate litigation, as this case demonstrates that it will be difficult for future plaintiffs to pursue design defect and negligence claims,\" they add. Shares rise 4.2%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679262867","title":"Bayer Wins First U.S. Trial over Roundup Since Supreme Court Ruling","url":"https://stock-news.laohu8.com/highlight/detail?id=2679262867","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679262867?lang=en_us&edition=fundamental","pubTime":"2026-10-30 15:24","pubTimestamp":1793345040,"startTime":"0","endTime":"0","summary":"A Missouri Circuit Court sided with Bayer's Monsanto business in a case over its Roundup weedkiller, handing the company a win in the first trial since the U.S. Supreme Court ruled in its favor in June.Bayer said late Thursday that the court jury ruled for Monsanto on the design defect, fraud, and negligence claims that each of the three plaintiffs pursued.The verdict came after the company won its Supreme Court challenge against claims that it failed to warn consumers that Roundup causes cancer and as it pursues a $7.25 billion settlement as part of a plan to move past long-running legal battles.The company said it would continue to back the safety of its glyphosate-based herbicides and defend its products in any remaining litigation.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679497571","title":"Bayer’s Vericiguat Heart Failure Study in India: What the Real‑World Data Could Mean for BAYRY","url":"https://stock-news.laohu8.com/highlight/detail?id=2679497571","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679497571?lang=en_us&edition=fundamental","pubTime":"2026-10-29 00:30","pubTimestamp":1793205037,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer’s latest update on NCT06632483 covers a completed observational study ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayers-vericiguat-heart-failure-study-in-india-what-the-realworld-data-could-mean-for-bayry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayers-vericiguat-heart-failure-study-in-india-what-the-realworld-data-could-mean-for-bayry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MNDmain","BAYRY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678228160","title":"Bayer Gets China Approval for Stroke-Prevention Drug in Global First for New Class","url":"https://stock-news.laohu8.com/highlight/detail?id=2678228160","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678228160?lang=en_us&edition=fundamental","pubTime":"2026-10-26 19:44","pubTimestamp":1793015040,"startTime":"0","endTime":"0","summary":"Bayer said it received regulatory authorization to launch a drug to prevent recurrent stroke in China, winning the first approval for a new class of blood-thinning medicines.The German pharmaceutical ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677056446","title":"Bayer Expands Real-World Kidney Data For Finerenone, Eyeing Long-Term Upside For BAYRY","url":"https://stock-news.laohu8.com/highlight/detail?id=2677056446","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677056446?lang=en_us&edition=fundamental","pubTime":"2026-10-22 00:30","pubTimestamp":1792600219,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer AG (BAYRY) is preparing a new real world study in Mexico to track fine...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayer-expands-real-world-kidney-data-for-finerenone-eyeing-long-term-upside-for-bayry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayer-expands-real-world-kidney-data-for-finerenone-eyeing-long-term-upside-for-bayry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676680555","title":"Bayer Advances Nurandociguat Tablet Study, Signaling Steady Progress in CKD Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2676680555","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676680555?lang=en_us&edition=fundamental","pubTime":"2026-10-20 00:30","pubTimestamp":1792427433,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer AG (BAYRY) has completed a Phase 1 study called “A Single Center, Open...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayer-advances-nurandociguat-tablet-study-signaling-steady-progress-in-ckd-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayer-advances-nurandociguat-tablet-study-signaling-steady-progress-in-ckd-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065732104.USD","BAYRY","BK4007","BK4097","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151971109","title":"Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1151971109","media":"Macro World","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151971109?lang=en_us&edition=fundamental","pubTime":"2026-10-03 17:22","pubTimestamp":1791019366,"startTime":"0","endTime":"0","summary":"","market":"other","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/3081.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/3081.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","BAYRY","VIR","SNY","PFE","ABT","ELIS","LLII","GILD","AMGN","GSKH","MRK","BMY","VERU","MRNA","GSK","BNTX","JNJ","NVOX","LLYX","ELIL","NVAX","NVOH","LLY","REGN","AZN","NVOC","NVS","NVO","MRNY","MRNX","BIIB"],"isVideo":true,"video":{"duration":206,"video_url":"https://news-video-sg.skytigris.cn/videos/cdn/3081.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/3081.webp","audio_url":"https://static.tigerbbs.com/f1bbc2b54742b92aafc704bc4d0c576c.mp3","isAI":true},"gpt_icon":0},{"id":"2672168746","title":"Bayer to invest $2.2B in new manufacturing site in New Albany, Ohio","url":"https://stock-news.laohu8.com/highlight/detail?id=2672168746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672168746?lang=en_us&edition=fundamental","pubTime":"2026-10-03 03:15","pubTimestamp":1790968514,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced plans to invest $2.2B in a new pharmaceutical manufacturing site in New Albany, Ohio, U.S. Building on more than $7B in U.S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-to-invest-2-2b-in-new-manufacturing-site-in-new-albany-ohio-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-to-invest-2-2b-in-new-manufacturing-site-in-new-albany-ohio-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LNGR","BAYRY","IEIH","EES","PJP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145285517","title":"Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=1145285517","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145285517?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:39","pubTimestamp":1790649592,"startTime":"0","endTime":"0","summary":"A federal judge in Delaware rejected a request on Monday from Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) to dismiss a lawsuit brought against them by Monsanto, a unit of German...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1929549753.HKD","LU0792757196.USD","LU2129689514.USD","LU1894683348.USD","LU1066051225.USD","IE00B3PB1722.GBP","LU0985481810.HKD","SG9999001440.SGD","LU1061106388.HKD","LU1883839398.USD","LU2456880835.USD","LU0432979614.USD","SG9999001176.USD","LU0225771236.USD","LU1066051811.HKD","IE0001KFT4U8.USD","LU2487616109.SGD","BK4534","IE00BSNM7G36.USD","LU1043141123.HKD","SG9999011175.SGD","LU0306806265.USD","BK4581","IXJ","LU1629891620.HKD","IE00BGHQF631.EUR","BK4599","IE00BDGV0183.EUR","LU2471134952.CNY","LU0072461881.USD","LU1989771016.USD","LU1935042991.SGD","IE000M9KFDE8.USD","BK4559","IE00B42XCP33.USD","LU2756315318.SGD","LU0210528500.USD","LU2129689431.USD","LU2602419157.SGD","LU0545562505.USD","IE0002141913.USD","LU1674673428.USD","LU1894683264.USD","LU0053666078.USD","BK4550","LU2236285917.USD","IDNA","LU1059921491.USD","LU2089984988.USD","LU0661504455.SGD","LU0345769128.USD","LU0057025933.USD","LU2213496289.HKD","LU0795875169.SGD","WDNA","LU0889566641.SGD","LU0640476718.USD","LU0426417589.USD","IE00B3T34201.USD","LU0820561909.HKD","IE00BFXG1179.USD","LU0122379950.USD","LU0964807845.USD","LU2505996681.GBP","LU0683600562.USD","LU1196500208.SGD","TRUH","LU0949170772.SGD","PJP","IE00B2B36J28.USD","LU1732800096.USD","LU2592432038.USD","BK4533","IE0002270589.USD","IE00BVYPNW00.USD","LU0124676726.USD","IE000MB6IJN5.SGD","LU0069063385.USD","LU1244550577.SGD","SGXZ57979304.SGD","BK4532","IE0009355771.USD","IE00B4R5TH58.HKD","LU1221951046.USD","IE00B1BXHZ80.USD","LU2430703178.SGD","JNJ","LU2403377893.USD","LU1057294990.SGD","LU0234570918.USD","LU0511384066.AUD","LU2750360641.GBP","IE0034235303.USD","LU2347655156.SGD","BK4535","LU0787776722.HKD","FHLC","LU1674673691.USD","BK4139","IE00B7SZLL34.SGD","BAYRY","LU2430703251.USD","IE00BN8TJ469.HKD","GNOM","IE000WAW04H5.SGD","LU1066051498.USD","MRNX","IYH","LU2112291526.USD","LU0689626769.HKD","LU0098860793.USD","LU1121112475.USD","IE000SO60NU8.SGD","BK4585","SG9999002232.USD","BK4501","LU0306807586.USD","LU2129689605.HKD","LU1430594728.SGD","LU0321505439.SGD","LU0882574055.USD","LU1778281490.HKD","SG9999013999.USD","LU1291159041.SGD","LU0162691827.USD","LU0289739343.SGD","LU1228905540.USD","IE00BKVL7J92.USD","LU2505996509.AUD","LU1732799900.SGD","LU0345769631.USD","LU0943347566.SGD","SG9999001176.SGD","VHT","SG9999002224.SGD","LU1003077747.HKD","LU0795875086.SGD","LU0985320562.USD","IE00B19Z3B42.SGD","SGXZ80539844.SGD","LU1066053197.SGD","LU1032466523.USD","LU0912757837.SGD","IE00BFTCPJ56.SGD","LU1221951129.SGD","LU0320765646.SGD","LU1585245621.USD","LU2471134879.HKD","BK4551","LU0321505868.SGD","MEDX","LU1551013342.USD","IE00B19Z3581.USD","LU0545039389.USD","LU2471134523.USD","LU0738911758.USD","BK4592","LU0170899867.USD","LU0114720955.EUR","BMED","LU1244550494.USD","LU2896262040.SGD","LU2023250330.USD","BK4007","LU1228905037.USD","LU0070217475.USD","RXL","LU1551013425.SGD","LU0345770993.USD","IE00BBT3K403.USD","LU0994945656.USD","OZEM","LU1718418525.SGD","LU2417539215.USD","IE000BZT7R73.USD","LU2430703095.HKD","IE00BJT1NW94.SGD","BK4568","LU0553294199.USD","IHE","LU0225284248.USD","LU0466842654.USD","LU1267930813.SGD","IE00BLSP4239.USD","LU1914381329.SGD","LU0210536198.USD","LU0203345920.USD","LU1032955483.USD","LU2133065610.SGD","LU0289961442.SGD","LU1145028129.USD","LU0234572021.USD","PFE","GDOC","LU0203347892.USD","LU2468319806.SGD","LU0426412945.USD","LU2750360997.AUD","LU2756315664.SGD","XLV","BK4548","BK4504","LU0456855351.SGD","IE000F7OJYX1.SGD","LU1244550221.USD","LU0472753341.HKD","LU2596442595.SGD","LU0058720904.USD","IE0000B7K699.USD","IE00BVYPNV92.GBP","LU1023059063.AUD","LU1074936037.SGD","LU1983299246.USD","LU1506573853.SGD","MRNA","LU1496350502.SGD","IE00BLSP4452.SGD","LU1162221912.USD","SG9999003800.SGD","BNTX","LU0820561818.USD","LU1261432733.SGD","JDOC","LU0820562030.AUD","LGHT","LU0868494617.USD","MRNY","LU2471134796.USD","LU0289739699.SGD","LU1043141396.HKD","IE00BJJMRZ35.SGD","IE00BZ1G4Q59.USD","LU1280957306.USD","LU0689472784.USD","LU0345770308.USD","BK4588","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670623274","title":"Bayer announces FDA accepts Lynkuet sNDA for Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2670623274","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670623274?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:10","pubTimestamp":1790597423,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application and granted Priorit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-announces-fda-accepts-lynkuet-snda-for-priority-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-announces-fda-accepts-lynkuet-snda-for-priority-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LABU","BK4588","BAYRY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}]}}